(Research Triangle Park, N.C.) BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer plans to provide a corporate summary and update regarding the Company’s clinical programs at the 7th Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, 2012 at 9 a.m. Eastern Time.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website at www.BioCryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst is advancing two preclinical programs towards IND filings: BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and BCX4161, an oral inhibitor of plasma kallikrein for hereditary angioedema. Utilizing state-of-the-art structure-guided drug design and crystallography, BioCryst continues to discover innovative compounds with the goal of addressing unmet medical needs of patients and physicians. For more information, please visit the Company’s website at www.BioCryst.com.